These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26342093)

  • 21. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
    Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
    Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I; Markatseli TE; Voulgari PV; Boki KA; Papadopoulos I; Settas L; Zisopoulos D; Skopouli FN; Iliopoulos A; Bertsias GK; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits.
    Ogrič M; Terčelj M; Praprotnik S; Tomšič M; Božič B; Sodin-Semrl S; Čučnik S
    Immunol Res; 2017 Feb; 65(1):172-185. PubMed ID: 27421721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards an individualised target concentration of adalimumab in rheumatoid arthritis.
    Ducourau E; Ternant D; Lequerré T; Fuzibet P; Le Loët X; Watier H; Goupille P; Paintaud G; Vittecoq O; Mulleman D
    Ann Rheum Dis; 2014 Jul; 73(7):1428-9. PubMed ID: 24550169
    [No Abstract]   [Full Text] [Related]  

  • 27. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
    J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
    Lieberman MR; Liebman TN; Alapati U; Khachemoune A
    Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats.
    Lee BY; Kwon KI; Kim MS; Baek IH
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):433-9. PubMed ID: 25725773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induced production of anti-etanercept antibody in collagen-induced arthritis.
    Yi H; Kim J; Jung H; Rim YA; Kim Y; Jung SM; Park SH; Ju JH
    Mol Med Rep; 2014 Jun; 9(6):2301-8. PubMed ID: 24718553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.
    Bombardieri S; Ruiz AA; Fardellone P; Geusens P; McKenna F; Unnebrink K; Oezer U; Kary S; Kupper H; Burmester GR;
    Rheumatology (Oxford); 2007 Jul; 46(7):1191-9. PubMed ID: 17504821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis.
    Aldrich MB; Velasquez FC; Kwon S; Azhdarinia A; Pinkston K; Harvey BR; Chan W; Rasmussen JC; Ross RF; Fife CE; Sevick-Muraca EM
    Arthritis Res Ther; 2017 May; 19(1):116. PubMed ID: 28566090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
    Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept.
    Priori R; Alessandri C; Magrini L; Cassarà EA; Ceccarelli F; Modesti M; Croia C; Bombardieri M; Valesini G
    Ann Rheum Dis; 2009 Sep; 68(9):1514-6. PubMed ID: 19674992
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation.
    Hsu LF; Huang JD
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):776-86. PubMed ID: 24887337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE
    Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.